# Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis

> **NCT02129777** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 122 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Namilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02129777
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-09
- **Final completion:** 2016-02
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02129777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02129777, "Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02129777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*